ES2388055T3 - Diagnóstico y estratificación de riesgo mediante NT-proET-1 - Google Patents
Diagnóstico y estratificación de riesgo mediante NT-proET-1 Download PDFInfo
- Publication number
- ES2388055T3 ES2388055T3 ES10191423T ES10191423T ES2388055T3 ES 2388055 T3 ES2388055 T3 ES 2388055T3 ES 10191423 T ES10191423 T ES 10191423T ES 10191423 T ES10191423 T ES 10191423T ES 2388055 T3 ES2388055 T3 ES 2388055T3
- Authority
- ES
- Spain
- Prior art keywords
- diagnosis
- diseases
- respiratory tract
- seq
- risk stratification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 34
- 238000013517 stratification Methods 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 38
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 26
- 210000004072 lung Anatomy 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 210000001124 body fluid Anatomy 0.000 claims abstract description 3
- 239000010839 body fluid Substances 0.000 claims abstract description 3
- 239000003550 marker Substances 0.000 claims description 22
- 238000004393 prognosis Methods 0.000 claims description 16
- 206010035664 Pneumonia Diseases 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 11
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 208000023504 respiratory system disease Diseases 0.000 claims description 9
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 102100034296 Natriuretic peptides A Human genes 0.000 claims description 8
- -1 NT -proANP Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 238000011156 evaluation Methods 0.000 claims description 6
- 238000003748 differential diagnosis Methods 0.000 claims description 5
- 230000005713 exacerbation Effects 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 4
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 4
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 4
- 101710187802 Natriuretic peptides B Proteins 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 229940124645 emergency medicine Drugs 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000001452 natriuretic effect Effects 0.000 claims description 4
- 230000002644 neurohormonal effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 101710187800 Natriuretic peptides A Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 102400000921 Gastrin Human genes 0.000 claims description 2
- 108010052343 Gastrins Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 2
- 102100030856 Myoglobin Human genes 0.000 claims description 2
- 108010062374 Myoglobin Proteins 0.000 claims description 2
- 102400001263 NT-proBNP Human genes 0.000 claims description 2
- 102100028427 Pro-neuropeptide Y Human genes 0.000 claims description 2
- 108010048233 Procalcitonin Proteins 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 2
- 108010072269 proendothelin 2 Proteins 0.000 claims description 2
- 108010072273 proendothelin 3 Proteins 0.000 claims description 2
- 108010088603 proneuropeptide Y Proteins 0.000 claims description 2
- 108010001670 prosomatostatin Proteins 0.000 claims description 2
- GGYTXJNZMFRSLX-UHFFFAOYSA-N prosomatostatin Chemical compound C1CCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NCC(=O)NC2C(NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(C(=O)NC(CO)C(=O)NC(CSSC2)C(O)=O)C(C)O)C(C)O)=O)N1C(=O)C(C)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(N)CO GGYTXJNZMFRSLX-UHFFFAOYSA-N 0.000 claims description 2
- 208000005333 pulmonary edema Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000003896 Myeloperoxidases Human genes 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 16
- 101800004490 Endothelin-1 Proteins 0.000 description 13
- 102400000686 Endothelin-1 Human genes 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N endothelin i Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010007558 Cardiac failure chronic Diseases 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000037081 physical activity Effects 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 206010007556 Cardiac failure acute Diseases 0.000 description 4
- 235000019687 Lamb Nutrition 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 201000004193 respiratory failure Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 208000016253 exhaustion Diseases 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 206010061736 Bronchitis bacterial Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 208000024796 pleuritic chest pain Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108010072272 proendothelin 1 Proteins 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007021443 | 2007-05-08 | ||
| DE102007021443A DE102007021443A1 (de) | 2007-05-08 | 2007-05-08 | Diagnose und Risikostratifizierung mittels NT-proET-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2388055T3 true ES2388055T3 (es) | 2012-10-08 |
Family
ID=39745333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10191423T Active ES2388055T3 (es) | 2007-05-08 | 2008-05-08 | Diagnóstico y estratificación de riesgo mediante NT-proET-1 |
| ES08758039T Active ES2430218T3 (es) | 2007-05-08 | 2008-05-08 | Diagnóstico y estratificación de riesgo mediante NT-proET-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08758039T Active ES2430218T3 (es) | 2007-05-08 | 2008-05-08 | Diagnóstico y estratificación de riesgo mediante NT-proET-1 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9261516B2 (enExample) |
| EP (2) | EP2306203B1 (enExample) |
| JP (2) | JP5717442B2 (enExample) |
| CN (2) | CN101688869B (enExample) |
| DE (1) | DE102007021443A1 (enExample) |
| ES (2) | ES2388055T3 (enExample) |
| WO (1) | WO2008135038A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| EP2472258A3 (en) | 2006-04-04 | 2012-11-28 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| JP5320294B2 (ja) * | 2006-10-26 | 2013-10-23 | ベー．エル．アー．ハー．エム．エス ゲーエムベーハー | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
| DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| US9229013B2 (en) * | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| WO2012059477A1 (en) * | 2010-11-01 | 2012-05-10 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment of patients with non-specific complaints |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| KR101531835B1 (ko) * | 2013-10-16 | 2015-06-29 | 한국표준과학연구원 | 화학적 동위원소 치환법을 이용한 혈액 내 뇌성 나트륨 이뇨 펩타이드 질량분석법 |
| CN106370856B (zh) * | 2016-08-16 | 2019-04-02 | 北京师范大学 | 肺纤维化的尿液蛋白标志物及其在诊断和预后中的用途 |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3519139B2 (ja) * | 1993-10-19 | 2004-04-12 | 武田薬品工業株式会社 | エンドセリン拮抗阻害剤スクリーニング用キット及びスクリーニング方法 |
| DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| KR20020068262A (ko) * | 1999-03-05 | 2002-08-27 | 에피제네시스 파마슈티칼스 아이엔씨 | 타겟 및 경로 유효/무효화 방법 |
| AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| EP2386863A1 (en) * | 2002-10-09 | 2011-11-16 | DMI Biosciences, Inc. | Diagnosis and monitoring of multiple organ failure |
| JP2007503393A (ja) * | 2003-08-22 | 2007-02-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｃｏｐｄ及び肺高血圧の治療方法 |
| EP1564558B1 (de) | 2004-02-13 | 2005-12-07 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens |
| US20050244839A1 (en) * | 2004-04-29 | 2005-11-03 | Cheung Siu T | Granulin-epithelin precursor (GEP) overexpression as a target for diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC) |
| EP1619505B1 (en) * | 2004-07-22 | 2008-04-16 | BRAHMS Aktiengesellschaft | Method for the diagnosis of critically ill patients |
| DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
| CA2596986A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il-17f in diagnosis and therapy of airway inflammation |
| JP2006292623A (ja) * | 2005-04-13 | 2006-10-26 | Univ Of Dundee | 心不全における突然死のマーカー |
| UA11822U (en) * | 2005-06-21 | 2006-01-16 | L T Malaia Inst Of Therapy Of | Method for determining the risk of the development and progressing of chronic obstructive pulmonary disease |
| WO2007013041A2 (en) * | 2005-07-29 | 2007-02-01 | Koninklijke Philips Electronics, N.V. | Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| DE102006060835A1 (de) * | 2006-12-22 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
-
2007
- 2007-05-08 DE DE102007021443A patent/DE102007021443A1/de not_active Withdrawn
-
2008
- 2008-05-08 JP JP2010506800A patent/JP5717442B2/ja active Active
- 2008-05-08 EP EP10191423A patent/EP2306203B1/de active Active
- 2008-05-08 WO PCT/DE2008/000781 patent/WO2008135038A2/de not_active Ceased
- 2008-05-08 EP EP08758039.5A patent/EP2147316B1/de active Active
- 2008-05-08 CN CN200880018171.XA patent/CN101688869B/zh not_active Expired - Fee Related
- 2008-05-08 ES ES10191423T patent/ES2388055T3/es active Active
- 2008-05-08 US US12/599,197 patent/US9261516B2/en not_active Expired - Fee Related
- 2008-05-08 CN CN201410468160.9A patent/CN104374926B/zh not_active Expired - Fee Related
- 2008-05-08 ES ES08758039T patent/ES2430218T3/es active Active
-
2014
- 2014-09-16 JP JP2014187690A patent/JP5932924B2/ja active Active
-
2016
- 2016-02-05 US US15/017,140 patent/US20160161505A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101688869B (zh) | 2014-09-17 |
| HK1203089A1 (en) | 2015-10-16 |
| US20110039283A1 (en) | 2011-02-17 |
| CN101688869A (zh) | 2010-03-31 |
| HK1139733A1 (en) | 2010-09-24 |
| EP2147316B1 (de) | 2013-07-10 |
| JP5932924B2 (ja) | 2016-06-08 |
| WO2008135038A3 (de) | 2009-02-05 |
| JP2015007653A (ja) | 2015-01-15 |
| EP2306203A1 (de) | 2011-04-06 |
| JP2010526305A (ja) | 2010-07-29 |
| JP5717442B2 (ja) | 2015-05-13 |
| EP2306203B1 (de) | 2012-07-11 |
| EP2147316A2 (de) | 2010-01-27 |
| US9261516B2 (en) | 2016-02-16 |
| US20160161505A1 (en) | 2016-06-09 |
| WO2008135038A2 (de) | 2008-11-13 |
| DE102007021443A1 (de) | 2008-11-13 |
| CN104374926B (zh) | 2017-05-17 |
| CN104374926A (zh) | 2015-02-25 |
| ES2430218T3 (es) | 2013-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2388055T3 (es) | Diagnóstico y estratificación de riesgo mediante NT-proET-1 | |
| ES2383711T3 (es) | Diagnóstico y estratificación de riesgos mediante el nuevo marcador CT-proADM | |
| JP2010526305A5 (enExample) | ||
| ES2250959T3 (es) | Determinacion en un liquido biologico de un peptido parcial de proadrenomedulina de la region media con fines diagnosticos e imnunoensayos para la realizacion de una determinacion de este tipo. | |
| US8465941B2 (en) | Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure | |
| ES2370071T3 (es) | Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina ii. | |
| ES2271674T3 (es) | Inmunoensayo tipo sandwich para la determinacion de peptidos parciales proanp. | |
| HK1139458B (en) | Diagnosis and risk stratification by means of the novel marker ct-proadm | |
| HK1139458A (en) | Diagnosis and risk stratification by means of the novel marker ct-proadm | |
| HK1139733B (en) | Diagnosis and risk stratification using nt-proet-1 | |
| HK1203089B (en) | Diagnosis and risk stratification using nt-proet-1 | |
| HK1197933A (en) | Diagnosis and risk stratification by means of the novel marker ct-proadm | |
| HK1197933B (en) | Diagnosis and risk stratification by means of the novel marker ct-proadm |